SCHEMBL23005196

SCHEMBL23005196

O=C(O)CCC(NC(=O)c1ncc(NC(=O)Oc2ccc([N+](=O)[O-])cc2)cc1Cl)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 8/20 0.50
FOLH1 Q04609 1/20 0.40
MTHFD1 P11586 1/20 0.39
MTHFD2 P13995 1/20 0.39
PTPN7 P35236 1/20 0.38
PTPN12 Q05209 1/20 0.38
PTPN22 Q9Y2R2 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
ITGB1 P05556 1/20 0.37
ITGA4 P13612 1/20 0.37
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
DGAT1 O75907 1/20 0.36
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23005195 1.00 FPR2 (0.50) FPR2FOLH1MTHFD1MTHFD2PTPN7
SCHEMBL23005128 0.90 FPR2 (0.50) FPR2FOLH1MTHFD1MTHFD2CA1
SCHEMBL23005129 0.90 FPR2 (0.50) FPR2FOLH1MTHFD1MTHFD2CA1
SCHEMBL30106797 0.84 L3MBTL1 (0.41) PTPN7PTPN12PTPN22KDM4EHPGD
SCHEMBL23005138 0.81 FPR2 (0.49) FPR2FOLH1MTHFD1MTHFD2CA1
SCHEMBL23005137 0.81 FPR2 (0.49) FPR2FOLH1MTHFD1MTHFD2CA1
SCHEMBL26915268 0.78 FOLH1 (0.50) FOLH1CA1CA2GAAMAPT
SCHEMBL8477195 0.78 FOLH1 (0.50) FOLH1CA1CA2GAAMAPT
SCHEMBL23005194 0.77 GAA (0.35) PTPN7PTPN12PTPN22GAAMAPT
SCHEMBL21494665 0.76 FPR2 (0.64) FPR2FOLH1MTHFD1MTHFD2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112218858-B 2, 6-Diamino-3, 4-dihydropyrimidin-4-one derivatives and their use in therapy 托马斯·黑勒戴药物研究基金会 2024-06-18 CN disclosed
EP-3781554-B1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) 2023-06-28 EP disclosed
US-20230110478-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2023-04-13 US disclosed
US-20210052587-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY MEDICINSK FORSKNING (SE) 2021-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230110478-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY IL2, THPO, IL6 FPR2 406/4885FOLH1 282/4885MTHFD1 2281/4885
US-20210052587-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY IL2, THPO, IL6 FPR2 435/4885FOLH1 315/4885MTHFD1 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.